Gefitinib

Description: Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation. Target: Tyrosine Kinases, EGFR, Autophagy. Smiles: N(C=1C2=C(C=C(OC)C(OCCCN3CCOCC3)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4. References: Noro R, et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer. 2006 Dec 6,6:277.